Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials

Conclusions A majority of the DLTs associated with AMKI in phase 1 trials are renal toxicities. Baseline hypertension and stage 3 CKD (NKF-KDOQI) might help to better identify patients at risk of AMKI-related renal toxicities.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research